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We retrospectively evaluated the efﬁcacy of immediate single instillation (SI) of pirarubicine hydro-
chloride (THP) in the chemoprevention of intermediate and high risk patients with non-muscle-invasive
bladder cancer (NMIBC). The study population consisted of 256 intermediate and high risk patients with
NMIBC who underwent Bacillus Calmette-Guerin (BCG) induction therapy or delayed intravesical
chemotherapy between 1999 and 2014. We introduced SI of 30 mg THP in 30 ml normal saline for all
cases in 2010, and thus earlier cases could be considered as historical controls. As BCG induction therapy,
patients received 80 mg of BCG Tokyo strain 2 weeks after transurethral resection of bladder tumor
(TURBT), and the instillations were repeated weekly for 8 weeks. On the other hand, as delayed
intravesical chemotherapy, patients received 30 mg THP in 30 ml normal saline over a period of 6 months
starting 2 weeks after TURBT. The instillation schedule was once a week for 1 month, every other week for
1 month and once a month for 4 months. The patients were followed with cystoscopy and urine cytology
every 3 months for the ﬁrst 2 years and every 6 months thereafter. The 3-, and 5-year non-recurrence rates
were 80. 3 and 80. 3%, respectively, in the single immediate instillation group and 69. 7 and 64. 5%,
respectively, in the control group. Univariate analysis revealed a signiﬁcant difference between the SI group
and the control group (P＝ 0. 025). Multivariate analysis showed that there was an independent and
signiﬁcant recurrence risk factor in selecting chemotherapy instead of BCG in additional intravesical
instillation therapy and not to perform SI. Limitations of our study are its retrospective and nonrandomized
nature with a limited number of patients.
(Hinyokika Kiyo 64 : 297-301, 2018 DOI : 10.14989/ActaUrolJap_64_7_297)
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緒 言
抗癌剤術後即時単回膀胱内注入療法 immediate single
instillation（SI）は，経 尿 道 的 膀 胱 腫 瘍 切 除 術
（TURBT）直後の浮遊腫瘍細胞の破壊と，残存する
微小腫瘍の化学的切除を目的として行われる．現在
EAU，NCCN および JUA ガイドラインでは，すべて
の筋層非浸潤性膀胱癌（NMIBC）で再発予防目的に
SI を行うことが推奨されている．低リスク NMIBC





中高リスク NMIBC における SI の再発予防効果につ
いて検討した．
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Table 1. Patient characteristics
Single immediate instillation No single immediate instillation P value
No of patients 96 160
Median age (years) (range) 72.8 (44-95) 69.2 (43-92) 0.006
Gender 0.777
Male 76 (79.2％) 129 (80.6％)
Female 20 (20.8％) 31 (19.4％)
Urinary cytology
I-III 48 (50.0％) 81 (50.6％) 0.923
IV-V 48 (50.0％) 79 (49.4％)
No of tumors
Single 20 (20.8％) 41 (25.6％) 0.384
Multiple 76 (79.2％) 119 (74.4％)
Tumor diameter
＜3 cm 82 (85.4％) 121 (75.6％) 0.061
≧3 cm 14 (14.6％) 39 (24.4％)
T-categoly
Ta 62 (64.6％) 89 (55.6％) 0.158
T1 34 (35.4％) 71 (44.4％)
Concurrent CIS
No 73 (76.0％) 136 (85.0％) 0.073
Yes 23 (24.0％) 24 (15.0％)
Tumor grade (2004 WHO)
Low grade 45 (46.9％) 79 (49.4％) 0.698
High grade 51 (53.1％) 81 (50.6％)
EAU risk group stratiﬁcation
Intermediate 37 (38.5％) 51 (31.9％) 0.277
High 59 (61.5％) 109 (68.1％)
Additional delayed bladder instillation
Chemotherapy 42 (43.8％) 89 (55.6％) 0.066
BCG 54 (56.3％) 71 (44.4％)
Second TUR
No 66 (68.8％) 127 (79.4％) 0.056
Yes 30 (31.3％) 33 (20.6％)
No of patients with recurrence 16 (16.7％) 62 (38.8％) ＜0.001
Median followup period (range) (months) 29.5 (4.2-66.6) 59.2 (3.0-187.4) 0.003
ラルビシン（THP）30 mg を生食 30 ml に溶解し使用
した．SI では，TURBT 直後に抗癌剤を膀胱内に注
入し，15分間保持した．抗癌剤維持膀胱内注入療法
は，原則的に TURBT 2 週間後より施行し，初めの
4回は毎週，次の 2回は隔週，その後の 4回は 4週ご
とに施行した．膀胱内注入時間は15分間とした．
BCG はイムノブラダー○R 40 mg あるいは 80 mg を生








尿細胞診を初めの 2年間は 3カ月ごと， 2∼ 5年は 6
カ月ごと， 5年以降は 1年ごとに施行した．SI の有
無別の群間比較は χ2 検定， t 検定および Mann-
Whitney 検定を用いた．また非再発率は，起算日を
TURBT 施行日とし Kaplan-Meier 法で算出した．有
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Fig. 1. Recurrence-free survival rate after transurethral resection. Kaplan-Meier
curves for recurrence-free survival according to immediate single instillation
groups.
Table 2. Univariate and multivariate analysis of risk factors for recurrence after transurethral resection
Univariate analysis Multivariate analysis
p-value HR (95％ CI) p-value
Age (≧70 vs ＜70) 0.086
Gender (Male vs Female) 0.436
Urinary cytology (I, II, III vs IV, V) 0.154
No of tumors (Soritary vs Multiple) 0.158
Tumor diameter (≧3 cm vs ＜3 cm) 0.763
T-category (Ta vs T1) 0.795
Concurrent CIS (Yes vs No) 0.642
Tumor grade (2004 WHO) (Low grade vs High grade) 0.264
EAU risk group stratiﬁcation (Intermediate vs High) 0.518
Additional delayed bladder instillation (Chemotherapy vs BCG) 0.007 0.552 (0.342-0.891) 0.015
Second TUR (Yes vs No) 0.107
Immediate single instillation (Yes vs No) 0.025 1.760 (1.002-3.093) 0.049
72.8および69.2歳で，有意に SI 施行群で高かった




は SI 施行群で54例（56.3％），SI 未施行群で71例
（44.4％），CIS 随伴例は SI 施行群で23例（24.0％），
SI 未施行群で24例（15.0％），セカンド TUR 施行例
は SI 施行群で30例（31.3％），SI 未施行群で33例
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Fig. 2. Recurrence-free survival rate after transurethral resection. Kaplan-Meier curves for recurrence-free survival
according to adjuvant treatment.









現在 EAU，NCCN および JUA ガイドラインではす







Sylvester らは SI 施行群と TUR 単独群のメタ解析を
行い， 1 年以内に 2 回以上再発した症例あるいは
























BCG 導入療法を行う症例に対する SI の再発予防効
果については，否定的な報告も散見されるが5,6)，
Abd El Morsen らは，MMC の即時膀胱内注入を施行
後引き続き MMC を週 1回ずつ 4回，その後 BCG を
月 1 回 1 年間施行した群と BCG を週 1 回ずつ 6 回
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剤維持療法が必要と述べていることから3)，SI には少
なくとも 1年程度の抗癌剤維持療法と同等の効果を持
つとすれば，SI＋BCG は BCG と抗癌剤の併用の側面
があるとも考えられ，BCG 施行例に対する SI の再発
予防効果が推測されると言える．本検討では BCG に
先行する SI は有意に再発率を低下させたことより，





SI 未施行群では 3 cm 以上の腫瘍径症例が多く，SI 施
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